New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
12:32 EDTANACAnacor price target raised to $35 from $29 at Wedbush
News For ANAC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
07:40 EDTANACAnacor price target raised to $80 from $70 at Jefferies
Jefferies analyst David Steinberg raised his price target for Anacor Pharmaceuticals to $80 from $70 saying Kerydin continues to exceed expectations. Sandoz has now fully completed its planned sales force expansion for the toenail fungus treatment, Steinberg tells investors in a research note, citing his industry contacts. Further, pivotal AN2728 Phase 3 data is expected in the coming weeks, the analyst points out. He ascribes 80% odds to a positive readout for the atopic dermatitis candidate, which he feels could push the shares past $100. Steinberg keeps a Buy rating on Anacor.
June 30, 2015
09:15 EDTANACAnacor price target raised to $85 from $72 at Wedbush
Wedbush believes that sales of Anacor's Kerydin drug have been impressive and could cause the company's Q2 results to beat expectations. The firm significantly raised its 2015-2017 Kerydin sales estimates and keeps an Outperform rating on Anacor.
June 29, 2015
08:35 EDTANACAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use